Cyxone AB is a clinical stage biotech company specializing in the development of transformative therapies against autoimmune and autoinflammatory diseases. Our pipeline includes rabeximod, currently in Phase 2 clinical development for the treatment of rheumatoid arthritis and T20K, currently in early clinical development for the treatment of multiple sclerosis.
Cyxone is listed on Nasdaq First North Growth Market since 2016 under the ticker CYXO.
Current treatment options for rheumatoid arthritis and multiple sclerosis have come a long way, however there is still a need to create safer and better treatments that provide an improved quality of life for the patient.
Rabeximod directly addresses the gap in the medical need for RA treatment. Combined with the convenience of oral administration and a beneficial safety and tolerability profile, rabeximod can be available for treatment in both early and later stages of the disease. It is cost-effective and will be positioned as a treatment option for a patient group who demonstrated inadequate response to the first-line treatment methotrexate.
T20K is a plant derived cyclotide that have demonstrated compelling immunomodulating properties impacting on T cell responses. In a preclinical model of multiple sclerosis (EAE model), T20K has been shown to significantly delay onset as well as severity of clinical symptoms by modulating T cells. This is a potentially disease preventing mechanism and T20K could thus be effective in slowing down the disease progression and even preventing disease flares and postponing the need of second-line treatments.